We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Specialist drugs sold by Big Pharma are so expensive that many patients are being excluded
Drugmaker taken to court by public interest group for abusing market position and profiteering
Amgen to launch ‘biosimilar’ version of medicine that has generated $200bn in sales since launch
AbbVie and Eli Lilly take action after clawback payments on branded drugs reach a quarter of UK sales
Federal Trade Commission votes 3-2 to approve tie-up between makers of Botox and Humira
Combination drug is being studied in several trials as a coronavirus treatment
Quarterly earnings beat expectations as cancer drug sales jump
Fund managers look for companies committed to protecting their balance sheet
More supportive central bank policy has provided a prop as leveraged companies hold back
Corporate issuance set to be among largest on record in US
AbbVie’s planned $63bn purchase of the Botox-maker will earn $123m for bank
Chicago-based pharmaceutical company reported better than expected earnings and revenue
Pipeline failures and drugs coming off patent lead to tie-up of pharma companies
Even desperate companies cannot count on shareholder support
Cash and stock offer marks latest blockbuster deal in healthcare sector
Blockbuster drug’s revenue outside US takes hit from new competition
Some companies pledge to lower costs if government reforms rebate system
Politicians to grill pharma executives over what is fast becoming a key election issue
Pharm group’s patent loss will be the gain of healthcare funders
As the European patent on AbbVie’s Humira expires, biosimilars are ready to target $20bn market
Drugmaker’s quarterly earnings beat Wall Street expectations
Doubts hang over acquisitions struck when the industry was in the grip of an M&A frenzy
Shareholders have lost faith after biotech titan failed to give substance to hype
Pharma group’s shares fall by 11 per cent after lung cancer drug setback
International Edition
